Market
Which injectable PrEP will dominate the market in South Africa by end of 2025?
2
Resolution / Starting Odds
Lenacapavir • 25%
Cabotegravir • 25%
Both equally • 25%
Neither dominates • 25%
Market research reports and sales data from pharmaceutical companies
Story
Lenacapavir Reduces HIV Infection Risk to Nearly 0% in Phase 3 Trial, Injectable Every Six Months
Dec 8, 2024, 03:45 PM
Lenacapavir, a novel pre-exposure prophylaxis (PrEP), has shown promising results in reducing the risk of HIV infection to nearly 0% in a phase 3 trial involving adolescent girls and young women in South Africa and Uganda. Unlike traditional vaccines, lenacapavir is an antiretroviral drug that inhibits HIV replication rather than training the immune system to recognize the virus. It is administered just under the skin every six months. Additionally, another injectable PrEP, cabotegravir, is available, requiring an injection every two months. Both options provide new avenues for HIV prevention, highlighting the evolving landscape of antiretroviral therapies.
View original story
Similar markets
Novartis • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
General adult population • 25%
Adolescent girls • 25%
Gender-diverse individuals • 25%
Other • 25%
50 to 80 countries • 25%
Less than 50 countries • 25%
More than 120 countries • 25%
81 to 120 countries • 25%
Other • 25%
USA • 25%
UK • 25%
South Africa • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
No • 50%
Yes • 50%
Hospitals • 25%
Pharmacies • 25%
Community health programs • 25%
Clinics • 25%
South Africa • 25%
United States • 25%
India • 25%
Other • 25%
Adherence • 25%
Regulatory Approval • 25%
Distribution • 25%
Cost • 25%
European Union • 25%
Other • 25%
United States • 25%
Africa • 25%